ERCC1 Isoform Expression and DNA Repair in Non–Small-Cell Lung Cancer
Top Cited Papers
- 21 March 2013
- journal article
- research article
- Published by Massachusetts Medical Society in New England Journal of Medicine
- Vol. 368 (12) , 1101-1110
- https://doi.org/10.1056/nejmoa1214271
Abstract
The excision repair cross-complementation group 1 (ERCC1) protein is a potential prognostic biomarker of the efficacy of cisplatin-based chemotherapy in non–small-cell lung cancer (NSCLC). Although several ongoing trials are evaluating the level of expression of ERCC1, no consensus has been reached regarding a method for evaluation. We used the 8F1 antibody to measure the level of expression of ERCC1 protein by means of immunohistochemical analysis in a validation set of samples obtained from 494 patients in two independent phase 3 trials (the National Cancer Institute of Canada Clinical Trials Group JBR.10 and the Cancer and Leukemia Group B 9633 trial from the Lung Adjuvant Cisplatin Evaluation Biology project). We compared the results of repeated staining of the entire original set of samples obtained from 589 patients in the International Adjuvant Lung Cancer Trial Biology study, which had led to the initial correlation between the absence of ERCC1 expression and platinum response, with our previous results in the same tumors. We mapped the epitope recognized by 16 commercially available ERCC1 antibodies and investigated the capacity of the different ERCC1 isoforms to repair platinum-induced DNA damage. We were unable to validate the predictive effect of immunostaining for ERCC1 protein. The discordance in the results of staining for ERCC1 suggested a change in the performance of the 8F1 antibody since 2006. We found that none of the 16 antibodies could distinguish among the four ERCC1 protein isoforms, whereas only one isoform produced a protein that had full capacities for nucleotide excision repair and cisplatin resistance. Immunohistochemical analysis with the use of currently available ERCC1 antibodies did not specifically detect the unique functional ERCC1 isoform. As a result, its usefulness in guiding therapeutic decision making is limited. (Funded by Eli Lilly and others.)Keywords
This publication has 41 references indexed in Scilit:
- The potential of exploiting DNA-repair defects for optimizing lung cancer treatmentNature Reviews Clinical Oncology, 2012
- Prognostic Role of ERCC1 in Advanced Non–Small-Cell Lung Cancer: A Systematic Review and Meta-AnalysisClinical Lung Cancer, 2011
- Cross-validation study of class III beta-tubulin as a predictive marker for benefit from adjuvant chemotherapy in resected non-small-cell lung cancer: analysis of four randomized trialsAnnals of Oncology, 2011
- ERCC1 and RRM1 in the International Adjuvant Lung Trial by Automated Quantitative in Situ AnalysisThe American Journal of Pathology, 2011
- Adjuvant chemotherapy, with or without postoperative radiotherapy, in operable non-small-cell lung cancer: two meta-analyses of individual patient dataThe Lancet, 2010
- Positive expression of ERCC1 predicts a poorer platinum-based treatment outcome in Chinese patients with advanced non-small-cell lung cancerMedical Oncology, 2009
- Immunohistochemical expression of BCRP and ERCC1 in biopsy specimen predicts survival in advanced non-small-cell lung cancer treated with cisplatin-based chemotherapyLung Cancer, 2008
- Interstrand crosslink repair: can XPF-ERCC1 be let off the hook?Trends in Genetics, 2008
- ERCC1 mRNA Expression Is Not Associated with Response and Survival after Platinum-Based Chemotherapy Regimens in Advanced Non-Small Cell Lung CancerJournal of Thoracic Oncology, 2007
- Adduct-specific monoclonal antibodies for the measurement of cisplatin-induced DNA lesions in individual cell nucleiNucleic Acids Research, 2006